- Home
- IAUX vs PGEN Comparison
IAUX vs PGEN Comparison
Compare IAUX & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAUX
- PGEN
- Stock Information
- Founded
- IAUX 2020
- PGEN 1998
- Country
- IAUX United States
- PGEN United States
- Employees
- IAUX N/A
- PGEN N/A
- Industry
- IAUX
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- IAUX
- PGEN Health Care
- Exchange
- IAUX Nasdaq
- PGEN Nasdaq
- Market Cap
- IAUX 507.4M
- PGEN 493.0M
- IPO Year
- IAUX N/A
- PGEN N/A
- Fundamental
- Price
- IAUX $0.75
- PGEN $4.18
- Analyst Decision
- IAUX Buy
- PGEN Buy
- Analyst Count
- IAUX 1
- PGEN 5
- Target Price
- IAUX $1.50
- PGEN $7.50
- AVG Volume (30 Days)
- IAUX 4.8M
- PGEN 15.4M
- Earning Date
- IAUX 08-13-2025
- PGEN 08-12-2025
- Dividend Yield
- IAUX N/A
- PGEN N/A
- EPS Growth
- IAUX N/A
- PGEN N/A
- EPS
- IAUX N/A
- PGEN N/A
- Revenue
- IAUX $76,622,000.00
- PGEN $4,340,000.00
- Revenue This Year
- IAUX $73.07
- PGEN $256.94
- Revenue Next Year
- IAUX $101.03
- PGEN $759.81
- P/E Ratio
- IAUX N/A
- PGEN N/A
- Revenue Growth
- IAUX 40.21
- PGEN N/A
- 52 Week Low
- IAUX $0.34
- PGEN $0.65
- 52 Week High
- IAUX $1.26
- PGEN $4.21
- Technical
- Relative Strength Index (RSI)
- IAUX 69.51
- PGEN 88.14
- Support Level
- IAUX $0.67
- PGEN $2.94
- Resistance Level
- IAUX $0.72
- PGEN $3.34
- Average True Range (ATR)
- IAUX 0.04
- PGEN 0.32
- MACD
- IAUX 0.02
- PGEN 0.22
- Stochastic Oscillator
- IAUX 96.63
- PGEN 99.00
About IAUX i-80 Gold Corp.
i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.